Connect with us


Tilray acquires Natura Naturals Holdings Inc with C$35 Million agreement



Tilray Incorporation, the global leader for cannabis cultivation, research, distribution, and production recently announced the closing for the acquisition of all outstanding and issues securities for Natura Naturals Holdings Incorporation. Henceforth, all the facilities by Natura shall operate as High Park Gardens. It will also serve as the cultivation facility for medical & adult-use of cannabis in Canada market.

As the final result of the acquisition, High Park and Tilray have acquired about 662,000sq.ft of the facility for greenhouse cultivation. Of this, 155,000sq.ft is currently licensed for use by the company. There have also been talks to expand this facility in order to increase overall production capacity. Natura is a completely-owned subsidiary based in Ontario’s Leamington serving as a fully-licensed cultivator adhering to Cannabis Act and specializing in the cultivation of greenhouse cannabis.

Under definite agreement terms, Tilray had delivered about C$35 million when closing the acquisition. About C$15 million from this way comprised of cash while another C$20 million was comprised of Tilray’s common stock in Class 2. Nature shareholders shall receive their portion from C$15 Million as closing amount post deduction of the transaction expenses paid by Natura along with applicable taxes.

Tilray currently handles 3 high-end facilities located in Canada with another located in Portugal. The firm by Natura to operate as the High Park Gardens shall cultivate the cannabis products at Leamington and has been designated to collaborate with the existing operations taking place in Ontario. High Park and Tilray also have a supply agreement for cannabis with licensees all through Canada. Recently, the companies also signed an exclusive deal for supply, sale, marketing, and distribution for delivering cannabis for High Park’s adult customers in Quebec. The close proximity of Tilray to High Park Gardens and the existing operations of High Park at Ontario shall be valuable for the long term collaboration for cultivation, research, and processing of cannabis within the firm.

Prior to the distribution, every cannabis product cultivated by High Park Gardens shall adhere professionally to the stringent production standards for quality assurance followed by Tilray. The increased stock supply from the inclusion of such production standard shall allow both High Park and Tilray to opt for the expansion of its supply capacity at the Canadian cannabis market. The company shall also opt for production of high-quality products for its brand. Tilray is the global pioneer dedicated to cultivation, production, distribution, and research of cannabis & cannabinoids as it currently serves 100s of 1000s of patients.

The team is a highly-timed and heavily-talented group who prides themselves on being discipline, diligent and dedicated daily in researching with an attention to detail for providing crystal clear clarity. As a whole, the editorial staff intends to uphold a promise in delivering today's cannabis news, CBD Oil hemp supplement announcements and user-friendly medical marijuana health guides. If you have Tips, News or want to Reach out: contact[@]

Continue Reading

Ultimate CBD Guide


ultimate-cbd-products-company-guidepopular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD is the most active daily CBD news publication featuring the latest cannabis industry stories and marijuana market trends. As the leader in CBD-centric content curation, we invite all readers to come for the headlines and stay for the insights. Quality is the top priority when presenting user guides, analyzing product reviews and reporting fact-checked news announcements. All information is for educational and informational purposes only. Disclaimer.

Got news? Email

Copyright © 2020 | Latest CBD News, Cannabis Guides and Marijuana Trends
Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.